Hostname: page-component-848d4c4894-89wxm Total loading time: 0 Render date: 2024-07-05T15:28:05.513Z Has data issue: false hasContentIssue false
  • English
  • Français

Antioxidant Therapy in Parkinson's Disease

Published online by Cambridge University Press:  05 January 2016

J. David Grimes ,
Mohamed N. Hassan  and
Jay Thakar
J. David Grimes*
Affiliation:
Parkinson's Disease Clinic & Laboratory, Ottawa Civic Hospital
Mohamed N. Hassan
Affiliation:
Parkinson's Disease Clinic & Laboratory, Ottawa Civic Hospital
Jay Thakar
Affiliation:
Parkinson's Disease Clinic & Laboratory, Ottawa Civic Hospital
*
Ottawa Civic Hospital, 1053 Carling Ave, Ottawa, Ontario, Canada Kl Y 4E9
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

It is postulated that endogenous oxidative mechanisms are a major factor in the continuing death of dopaminergic neurons and the progression of Parkinson's disease. Scientific evidence in support of, and negating, the free radical auto-toxicity and dopamine toxicity concepts is reviewed. There is conflicting evidence whether free radicals are involved in the toxicity of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and attempts to prevent the toxicity of MPTP with antioxidant therapy have had variable results. The oxidation of dopamine by monoamine oxidase produces toxic metabolites however animal studies with high dose longterm levodopa and MPTP have failed to show clear evidence for autoxidation. Firm supportive evidence is obtained from the monoamine oxidase B inhibitor experience which demonstrated a block of the toxicity of MPTP in animals and probable prolongation of the course of human Parkinson's disease.

The scientific data available is inconclusive but there is significant hope of retarding progressive catecholaminergic neuron degenerative changes by augmenting the free radical scavenging system with antioxidants (such as Vitamin E) and slowing catecholamine oxidation by monoamine oxidase B inhibition. Careful clinical trials with these agents must be performed.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 14 , Issue S3 , August 1987 , pp. 483 - 487
Copyright
Copyright © Canadian Neurological Sciences Federation 1987

References

REFERENCES

1.Shaw, KM, Lees, AJ, Slern, GM. The impact of treatment with levodopaonParkinson’s disease. QJ Med 1983: 49(195): 283–293.Google Scholar
2.Melamed, E. Initiation of levodopa therapy in Parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol 1986: 43: 402–405.CrossRefGoogle ScholarPubMed
3.Ballard, PA, Tetrud, JW, Langston, JW. Permanent human parkinsonism due to l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP): Seven cases. Neurology 1985: 35: 949–956.CrossRefGoogle Scholar
4.Snyder, SH, D’Amato, RJ. MPTP: A neurotoxin relevant to the pathophysiology of Parkinson’s disease. Neurology 1986; 36: 250–258.CrossRefGoogle Scholar
5.Burns, RS, LeWitt, PA, Ebert, MH. et al. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-Me-thyl-4-phenyl-l,2,3,6-tetrahydropyridine(MPTP).? Engl J Med 1985; 312(22): 1418–1421.CrossRefGoogle ScholarPubMed
6.Davis, GC, Williams, AC, Markey, SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatric Res. 1979; 1: 249–254.CrossRefGoogle ScholarPubMed
7.Barbeau, A. Etiology of Parkinson’s disease: A research strategy. Can J Neurol Sci 1984; 11: 24–28.CrossRefGoogle ScholarPubMed
8.Calne, DB, Langston, JW. Hypothesis. Aetiology of Parkinson’s disease. Lancet 1983; 1: 1457–1459.CrossRefGoogle Scholar
9.Ambani, LM, Van Woert, WH, Murphy, S. Brain peroxidase and catalase in Parkinson’s disease. Arch Neurol 1975; 32: 114–118.CrossRefGoogle Scholar
10.Perry, TL, Godin, DV, Hansen, S. Parkinson’s disease: A disorder due to nigral glutathione deficiency? Neurosci Lett 1982; 33: 305–310.CrossRefGoogle ScholarPubMed
11.Graham, DG. Catecholamine toxicity: A proposal for the molecular pathogenesis of managanese neurotoxicity and Parkinson’s disease. Neurotoxicology 1984; 1: 83–96.Google Scholar
12.Kopin, IJ, Markey, SP, Burns, JN. et al. Mechanisms of neurotoxicity of MPTP. In: Fahn, S, ed. Recent Developments in Parkinson’s Disease Raven Press, N.Y. 1986; 169–173.Google Scholar
13.Baron, JA. Cigarette smoking and Parkinson’s disease. Neurology 1986; 36: 1490–1496.CrossRefGoogle ScholarPubMed
14.Einarson, L. Deposits of fluorescent acid-fast products in the nervous system and skeletal muscles of adult rats with chronic Vitamin-? deficiency. J Neurol Neurosurg Psychiat 1953; 16: 98–109.CrossRefGoogle Scholar
15.Nelson, JS, Fitch, CD, Fischer, VW, el al. Progressive neuropathology lesions in Vitamin?-deficient rhesus monkeys. J of Neuropathol Exp Neurol 1981; 40(2): 166–186.CrossRefGoogle Scholar
16.Noda, Y, McGeer, PL, McGeer, EG. Lipid peroxides in brain duringaging and Vitamin? deficiency: Possible relations to changes in neurotransmitter indices. Neurobiol Aging 1982; 3: 173–178.CrossRefGoogle ScholarPubMed
17.Perry, TL, Yong, VW, Clavier, RM, et al. Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-l,2,3,6-tetrahy-dropyridine by four different antioxidants in the mouse. Neurosci Lett 1985; 60: 109–114.CrossRefGoogle Scholar
18.Baldessarini, RJ, Kula, NS, Francoeur, D, et al. Antioxidants fail to inhibit depletion ofstriatal dopamine by MPTP. Neurology 1986; 36: 735.CrossRefGoogle Scholar
19.Chiba, K, Trevor, A Jr., Castagnoli, N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984; 120(2): 574–578.CrossRefGoogle ScholarPubMed
20.Cohen, G. The pathobiology of Parkinson’s disease: Biochemical aspects of dopamine neuron senescence. J Neural Trans. 1983; Suppl 19: 89–103.Google ScholarPubMed
21.Slivka, A, Cohen, G. Hydroxyl radical attack on dopamine. J Biol Chem 1985; 260(29): 15466–15472.CrossRefGoogle ScholarPubMed
22.Robinson, DS. Changes in monoamine oxidase and monoamines with human development and aging. Fed Proc 1975:34: 103–107.Google ScholarPubMed
23.Birkmayer, W, Knoll, J. Riederer, P, et al. Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson’s disease: A longterm study. J Neural Trans 1985; 65: 113–127.CrossRefGoogle Scholar
24.Calne, DB, Duvoisin, RC, McGeer, E. Speculations on the etiology of Parkinson’s disease. Adv Neurol 1984; 40: 353–360.Google ScholarPubMed
25.Kappus, H. Lipid peroxidation: Mechanisms, analysis, enzymology and biological relevance. In: Sies, H, ed. 1985 Oxidative Stress, Academic Press, London, 273–310.CrossRefGoogle Scholar
26.Cohen, G. Oxidative Stress in the nervous system. In: Sies, H, ed. 1985 Oxidative Stress, Academic Press, London. 383–402.CrossRefGoogle Scholar
27.Heikkila, RE, Cohen, G. Inhibition of biogenic amine uptake by hydrogen peroxide: A mechamism for toxic effects of 6-hydro-xydopamine. Science 1971: 172: 1257–1258.CrossRefGoogle Scholar
28.Poirier, J, Donaldson, J, Barbeau, A. The specific vulnerability of substantia nigra to MPTP is related to the presence of transition metals. Biochem Biophys Res Commun 1985; 128(1): 25–33.CrossRefGoogle Scholar
29.Drayer, B, Burger, P, Darwin, R, et al. Magnetic resonance imaging of brain iron. AJNR 1986; 7: 373–380.Google Scholar
30.Smith, MT, Sandy, MS, Di Monte, D. Free radicals, lipid peroxidation, and Parkinson’s disease. Lancet 1987: 1: 38.CrossRefGoogle ScholarPubMed
31.Yong, VW, Perry, TL, Krisman, AA. Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-l,2,3,6-tetra-hydropyridine is prevented by antioxidant pretreatment. Neurosci Lett 1986; 63: 56–60.CrossRefGoogle Scholar
32.Sershen, H, Reith, MEA, Hashim, A, et al. Protection against l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine neurotoxicity by the antioxidant ascorbic acid. Neuropharmacology 1985:24(12): 1257–1259.CrossRefGoogle Scholar
33.Wagner, GC, Jarvis, MF, Carelli, RM. Ascorbic acid reduces the dopamine depletion induced by MPTP. Neuropharmcology 1985; 24(12): 1261–1262.CrossRefGoogle ScholarPubMed
34.Langston, JW, Irwin, I. MPTP: Current concepts and controversies. Clin Neuropharmacology 1986; 9(6): 485–507.CrossRefGoogle ScholarPubMed
35.Sahakian, BJ, Carlson, KR, DeGirolami, U, et al. Functional and structural consequences of longterm dietary L-Dopa treatment in mice. Commun Psychopharmacol 1980; 4: 169–176.Google ScholarPubMed
36.Hefti, F, Melamed, E, Bhawan, J, et al. Long-term administration of L-Dopa does not damage dopaminergic neurons in the mouse. Neurology 1981: 31: 1194–1195.CrossRefGoogle Scholar
37.Quinn, N, Parkes, D, Janota, I, et al. Preservation of substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Movement Disorders 1986; 1(1): 65–68.CrossRefGoogle Scholar
38.Seiden, LS, Vosmer, G. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmacol Biochem Behav 1984: 21: 29–31.CrossRefGoogle ScholarPubMed
39.D’Amato, RJ, Lipman, ZP, Snyder, SH. Selectivity of the Parkinsonian neurotoxin MPTP: Toxic metabolite MPP+ binds to Neuromelanin. Science 1986; 231: 987–989.CrossRefGoogle ScholarPubMed
40.Thaw, HH, Collins, VP, Brunk, UT. Influence of oxygen tension, pro-oxidant and antioxidants on the formation of lipid peroxidation products (lipofuscin) in individual cultivated human glial cells. Mech Aging Develop 1984: 24: 211–223.CrossRefGoogle ScholarPubMed
41.Bannon, MJ, Goedert, M, Williams, B. The possible relation of glutathione, melanin and l-methyl-4-phenyl-l ,2,5,6-tetra-hydropyridine (MPTP) to Parkinson’s disease. Biochem Pharm 1984: 33(17): 2697–2698CrossRefGoogle Scholar
42.Hornykiewicz, O. Brain neurotransmitter changes in Parkinson’s disease. In: Marsden, CD. Fahn, S, eds. Movement Disorders, Vol 1. Butterworth, Boston, 41–58.Google Scholar
43.McGeer, PL, McGeer, EG, Suzuki, JS. Aging and extrapyramidal function. Arch Neurol 1977: 34: 33–35.CrossRefGoogle ScholarPubMed
44.Spencer, P, Calne, DB, McGeer, E, et al. Alzheimer’s disease, Parkinson’s disease, and motoneurone disease: Abiotropic interaction between ageing and environment? Lancet 1986: 2: 1067–1070.Google Scholar
45.Rajput, AH, Uitti, RJ, Laverty, W, et al. Early onset Parkinson’s disease in Saskatchewan - Environmental considerations for etiology. Can J Neurol Sci 1986; 13: 312–316.CrossRefGoogle ScholarPubMed
46.Jarvis, MF, Wagner, GC. Age-dependent effects of l-methyl-4-phenyl-1,2,5,6-tetrahydropyridine(MPTP). Neuropharmacology 1985; 24(6): 581–583.CrossRefGoogle Scholar
47.Forno, LS, Langston, JW, DeLanney, LE, et al. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986; 20: 449–455.CrossRefGoogle ScholarPubMed
48.Ramsden, DB, Williams, AC. Production in nature of compound resembling methylphenyltetrahydropyridine, A possible cause of Parkinson’s disease. Lancet 1985; 1: 215.CrossRefGoogle ScholarPubMed
49.Fellman, JH, Nutt, JN. MPTP-like molecules and Parkinson’s disease. Lancet 1985; 1: 924.CrossRefGoogle ScholarPubMed
50.Testa, B, Naylor, R, Costall, B, et al. Does an endogenous methy-Ipyridinium analogue cause Parkinson’s disease? J Pharm Pharmacol 1985; 37: 679–680.CrossRefGoogle ScholarPubMed
51.Barbeau, A. Roy, M, Paris, S. et al. Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet 1985: 2: 1213–1216.CrossRefGoogle ScholarPubMed
52.Spencer, PS. Nunn, PB. Hugon, J, et al. Motorneurone Disease on Guam: Possible role of a food neurotoxin. Lancet 1986; 1: 965.CrossRefGoogle ScholarPubMed
53.Mandell, HG, Cohn, VH. Fat soluble vitamins. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 7th Edition. Macmillian, N.Y. 1985; 1573–1591.Google Scholar
54.McCay, PB, King, MM. Vitamin E: Its role as a biological free radical scavenger and its relationship to the microsomal mixed-function oxidase system. In: Vitamin E: A Comprehensive Treatise. Machlin, LJ, ed. Dekker, N.Y. 1980: 289–317.Google Scholar
55.Quintanilha, AT, Packer, L. Davies, JMS. et al. Membrane effects of itamin ? deficiency: Bioenergetic and surface charge density studies of skeletal muscle and liver mitochondria. In: Vitamin E: Biochemical, Hematological, and Clinical Aspects, Lubin, B. Machlin, LJ, eds. Annals N.Y. Acad Sci 1982: 393: 32–47.CrossRefGoogle Scholar
56.Diplock, AT. The role of Vitamin ? in biological membranes. In: Biology of Vitamin? (Ciba Foundation Symposium 101). Pitman. London 1983: 45–55.Google ScholarPubMed
57.Satya-Murti, S, Howard, L, Krohel, G, et al. The spectrum of neurologic disorder from Vitamin? deficiency. Neurology 1986: 36: 917–921.CrossRefGoogle Scholar
58.Muller, DPR. Lloyd, JK. Wolff, OH. Vitamin? and Neurological Function. Lancet 1983: 1: 225–228.CrossRefGoogle ScholarPubMed
59.Brin, MF, Pedley, TA, Lovelace, RE. et al. Electrophysiologic fea-tures of abetalipoproteinemia: Functional consequences of vitamin? deficiency. Neurology 1986: 36: 669–673.CrossRefGoogle Scholar
60.Riederer, P, Youdim, MB. Monoamine oxidase activity and monoamine metabolism in brains of Parkinsonian treated l-Deprenyl. J Neurochem 1986:46(5): 1359–1365.CrossRefGoogle ScholarPubMed
61.Cohen, G. Pasik, P. Cohen, B. et al. Pargyline and deprenyl prevent the neurotoxicity of l-methyl-4-phenyl-I.2.3.6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 1985; 106: 209–210.CrossRefGoogle Scholar
62.Willson, RL. Free radical protection: why vitamine?. not vitamin C, B-carotene or glutathione? In: Biology of Vitamin E. (Ciba Foundation Symposium 101). Pitman. London. 1983: 19–44.Google Scholar
63.Elsworth, JD. Glover, V. Reynolds, G P. et al. Deprenyl administration in man: a selective monoamine oxidase ? inhibitor without the ‘cheese effect’. Psychopharmacology 1978: 57: 33–38.CrossRefGoogle Scholar
64.Yahr, MD, Mendoza, MR, Moros, D. et al. Treatment of Parkinson’s disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline). Acta Neurol Scand 1983; 95: 95–102.CrossRefGoogle ScholarPubMed